Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department
Recruiting · NCT07202507 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Oscar Lambret
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit. Researchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being. Participants will: * Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles * Complete self-report questionnaires on anxiety, depression, quality of life, and nausea * Receive 45-minute Snoezelen sessions every two days during their second hospitalization * Participate in a semi-structured interview after the final session * Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations
Who can take part
Inclusion criteria
- New patient
- Treated in the Paediatrics/AJA department of the Oscar Lambret Centre for cancer (all types of cancer)
- Hospitalisation for several days
- Highly emetogenic chemotherapy treatment: this corresponds to all in-patient treatments carried out in the Paediatrics/AJA department.
- Age at diagnosis : ≥ 8 years and \< 18 years.
- French language
- Information for the patient and those with parental authority; consent signed by the patient and those with parental authority.
- Valid social security cover
Exclusion criteria
- Contraindication to SNOEZELEN:
- Claustrophobia
- Presence of psychiatric, addictive or cognitive disorders that would prevent compliance with the protocol requirements;
- State of health not allowing participation in the study (severe fatigue, symptoms refractory to treatment).
- Pregnant or breast-feeding women
Where it is running
1 location listed.
- Centre Oscar Lambret - Lille, France